Q-linea AB (publ) announced early study results show ASTar prompted antibiotic therapy modifications in up to 45% of septic patients and enabled appropriate care 20 ? 34 hours earlier than current standard-of-care. This weekend, results from two clinical studies on rapid AST were presented at the AMCLI (Associazione Microbiologi Clinici Italiani) National Congress, in Rimini, Italy, at a workshop hosted by Q-linea.

Prof. Maurizio Sanguinetti from Università Cattolica del Sacro Cuore, Rome, shared interim results from the LIFETIMES study. Data from ICU patients with bloodstream infections revealed that ASTar prompted antibiotic therapy modifications in 45% of cases, occurring 1.5 days (34.1 hours) earlier than current standard-of-care. Similarly, study results presented by Prof. Alexia Verroken from Cliniques Universitaires Saint-Luc, Brussels, demonstrated that ASTar implementation reduced the time to optimal treatment by nearly 20 hours (19 hours and 53 minutes) compared to routine methods.

Prof. Verroken?s work indicated that optimal integration of ASTar within the workflow could result in change in therapy selection in one out of four patients. The data presented showed that where ASTar determined clinical impact, 33.3% involved de-escalation, 55% involved escalation and 11.1% involved antibiotic switch.